small molecule

OJEMDA

TOVORAFENIB

Loss of exclusivityJune 2035latest FDA-listed patent expiry

CompanyDAY ONE BIOPHARMACEUTICALS INC

Drug detail

Brand name	OJEMDA
Active ingredient	TOVORAFENIB
Strength	25MG/ML
Dosage form	FOR SUSPENSION
Route	ORAL
Modality	Small molecule
FDA approval	April 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
10426782	June 2035	product
8293752	August 2031	substance, product

Regulatory exclusivity

Code	Expires
ODE-478	April 2031
NCE	April 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from DAY ONE BIOPHARMACEUTICALS INC